Interleukin 20
| IL20 | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| Wikidata | ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
Interleukin 20 (IL20) is a protein that is in humans encoded by the IL20 gene which is located in close proximity to the IL-10 gene on the 1q32 chromosome.[5][6] IL-20 is a part of an IL-20 subfamily which is a part of a larger IL-10 family.[5]
IL-20 subfamily also includes other
IL-20 requires an
Function
IL-20 has a broad range of functions and is involved in a variety of immune and non-immune processes in the body.[5] For example, IL-20 is involved in the process of wound healing, proliferation of epithelial cells, prevention of apoptosis of epithelial cells,[5] regulation of differentiation of keratinocytes during inflammation, the expansion of multipotential hematopoietic progenitor cells, and more.[10]
A specific receptor for this cytokine is highly upregulated in psoriatic skin.[6][11] Dysfunctional regulation of IL-20 could lead to uncontrollable wound healing in psoriasis, which could be a contributing factor to the pathogenesis of this disease.[11]
Because IL-20 is involved in the promotion of
IL-20 is an angiogenesis factor and is highly expressed in artery plaques found in patients with atherosclerosis.[14]
In rheumatoid arthritis
IL-20 is involved in many stages of
Antibody
Anti-IL-20 monoclonal antibodies have been researched as clinical candidates for the treatment or prevention of psoriasis, rheumatoid arthritis, atherosclerosis, osteoporosis, and stroke.[10][17][19] The anti-IL-20 antibody has been shown to reduce the severity of RA in rats, mitigate bone destruction, and more. The anti-IL-20 antibody neutralizes not only IL-20 signaling but also decreases TNF-α, IL-1, and IL-6 signaling in vivo.[15][18] A human recombinant monoclonal antibody against IL-20 developed by Novo Nordisk Inc. now entered the IIb phase of a clinical trial.[15]
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000162891 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000026416 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ S2CID 29114703.
- ^ PMID 11860351.
- PMID 21166540.
- S2CID 1870754.
- ^ "Entrez Gene: Interleukin 20".
- ^ PMID 26968800.)
{{cite journal}}: CS1 maint: DOI inactive as of February 2024 (link - ^ S2CID 20474354.
- ^ PMID 22962576.
- PMID 18521188.
- S2CID 8237021.
- ^ PMID 26297177.
- PMID 16947773.
- ^ PMID 18061474.
- ^ S2CID 10729459.
- PMID 21844205.
External links
- Overview of all the structural information available in the PDB for UniProt: Q9NYY1 (Interleukin-20) at the PDBe-KB.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.